Drug Patents owned by Array Biopharma Inc
1. List of Braftovi drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US8946250 | ARRAY BIOPHARMA INC | 3,4-diarylpyrazoles as protein kinase inhibitors |
Jul, 2029
(6 years from now) | |
| US8541575 | ARRAY BIOPHARMA INC | 3,4-diarylpyrazoles as protein kinase inhibitors |
Feb, 2030
(6 years from now) | |
| US9593099 | ARRAY BIOPHARMA INC | Compounds and compositions as protein kinase inhibitors |
Aug, 2030
(7 years from now) | |
| US8501758 | ARRAY BIOPHARMA INC | Compounds and compositions as protein kinase inhibitors |
Aug, 2030
(7 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10005761 | ARRAY BIOPHARMA INC | Compounds and compositions as protein kinase inhibitors |
Aug, 2030
(7 years from now) | |
| US9850230 | ARRAY BIOPHARMA INC | Compounds and compositions as protein kinase inhibitors |
Aug, 2030
(7 years from now) | |
| US9850229 | ARRAY BIOPHARMA INC | Compounds and compositions as protein kinase inhibitors |
Aug, 2030
(7 years from now) | |
| US9593100 | ARRAY BIOPHARMA INC | Compounds and compositions as protein kinase inhibitors |
Aug, 2030
(7 years from now) | |
| US9314464 | ARRAY BIOPHARMA INC | Compounds and compositions as protein kinase inhibitors |
Jul, 2031
(8 years from now) | |
| US10258622 | ARRAY BIOPHARMA INC | Method of treating colorectal cancer by administration of pharmaceutical formulations of (S)-methyl (1-((4-(3-(5-chloro-2-fluoro-3-(methylsulfonamido)pheny1)-1-isopropyl-1H-pyrazol-4-yl)pyrimidin-2-yl)amino)propan-2-yl) carbamate |
Nov, 2032
(9 years from now) | |
| US9387208 | ARRAY BIOPHARMA INC | Pharmaceutical formulations of (S)-methyl (1-((4-(3-(5-chloro-2-fluoro-3-(methylsulfonamido)phenyl)-1-isopropyl-1H-pyrazol-4-yl)pyrimidin-2-yl)amino)propan-2-yl)carbamate |
Nov, 2032
(9 years from now) | |
| US9763941 | ARRAY BIOPHARMA INC | Method of treating melanoma by administration of pharmaceutical formulations of (S)-methyl (1-((4-(3-(5-chloro-2-fluoro-3-(methylsulfonamido)phenyl)-1-isopropyl-1H-pyrazol-4-yl)pyrimidin-2-yl)amino)propan-2-yl)carbamate |
Nov, 2032
(9 years from now) | |
| US9474754 | ARRAY BIOPHARMA INC | Pharmaceutical combinations comprising a B-RAF inhibitor, and EGFR inhibitor and optionally a PI3K-α inhibitor |
Aug, 2033
(10 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | Jun 27, 2023 |
| Orphan Drug Exclusivity (ODE) | Jun 27, 2025 |
| New Indication (I) | Apr 8, 2023 |
Drugs and Companies using ENCORAFENIB ingredient
NCE-1 date: 2022-06-27
Market Authorisation Date: 27 June, 2018
Treatment: Treatment of melanoma; Braftovi is a kinase inhibitor indicated in combination with cetuximab, for the treatment of adult patients with metastatic colorectal cancer (crc) with a braf v600e mutation, a...
Dosage: CAPSULE;ORAL
BRAFTOVI family patents
28
United States
9
European Union
8
Japan
6
China
5
Spain
5
Hong Kong
5
Denmark
5
Poland
5
EA
5
Croatia
5
Portugal
5
Lithuania
5
Slovenia
5
Hungary
4
RS
4
Brazil
4
Canada
4
Singapore
4
Cyprus
4
Peru
4
Chile
4
Mexico
4
Australia
3
Ukraine
3
Morocco
3
Argentina
3
New Zealand
3
Korea, Republic of
3
Guatemala
3
Israel
3
Colombia
3
Tunisia
2
Philippines
2
Malaysia
2
India
2
ME
2
San Marino
2
Taiwan
2
Jordan
2
Ecuador
2
South Africa
1
Uruguay
1
Austria
1
Dominican Republic
1
Turkey
1
Norway
1
Nicaragua
1
Honduras
1
Georgia
1
Cuba
1
Costa Rica
1
Netherlands
1
Luxembourg
2. List of Mektovi drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US7777050 | ARRAY BIOPHARMA INC | N3 alkylated benzimidazole derivatives as MEK inhibitors |
Mar, 2023
(2 months ago) | |
| US8178693 | ARRAY BIOPHARMA INC | N3 alkylated benzimidazole derivatives as MEK inhibitors |
Mar, 2023
(2 months ago) | |
| US9562016 | ARRAY BIOPHARMA INC | Preparation of and formulation comprising a MEK inhibitor |
Oct, 2033
(10 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8193229 | ARRAY BIOPHARMA INC | Method of treatment using N3 alkylated benzimidazole derivatives as MEK inhibitors |
Mar, 2023
(2 months ago) | |
| US8513293 | ARRAY BIOPHARMA INC | Methods of treating a hyperproliferative disorder or inhibiting cell growth in a mammal |
Mar, 2023
(2 months ago) | |
| US9593100 | ARRAY BIOPHARMA INC | Compounds and compositions as protein kinase inhibitors |
Aug, 2030
(7 years from now) | |
| US10005761 | ARRAY BIOPHARMA INC | Compounds and compositions as protein kinase inhibitors |
Aug, 2030
(7 years from now) | |
| US9850229 | ARRAY BIOPHARMA INC | Compounds and compositions as protein kinase inhibitors |
Aug, 2030
(7 years from now) | |
| US9314464 | ARRAY BIOPHARMA INC | Compounds and compositions as protein kinase inhibitors |
Jul, 2031
(8 years from now) | |
| US9980944 | ARRAY BIOPHARMA INC | Preparation of and formulation comprising a MEK inhibitor |
Oct, 2033
(10 years from now) | |
| US9598376 | ARRAY BIOPHARMA INC | Preparation of and formulation comprising a MEK inhibitor |
Oct, 2033
(10 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | Jun 27, 2023 |
| Orphan Drug Exclusivity (ODE) | Jun 27, 2025 |
Drugs and Companies using BINIMETINIB ingredient
NCE-1 date: 2022-06-27
Market Authorisation Date: 27 June, 2018
Treatment: Method of treating melanoma; Indicated in combination with encorafenib for the treatment of melanoma; Indicated in combination with encorafenib for the treatment of melanoma with a braf mutation; Indi...
Dosage: TABLET;ORAL
MEKTOVI family patents
41
United States
10
China
10
Japan
10
European Union
9
Spain
8
Poland
7
Denmark
7
Cyprus
7
Portugal
7
Slovenia
6
Brazil
6
Argentina
6
Hungary
5
Hong Kong
5
Dominican Republic
5
Iceland
5
Canada
5
Singapore
5
Korea, Republic of
5
Israel
5
Taiwan
4
Russia
4
Australia
4
Lithuania
3
Chile
3
Mexico
3
South Africa
2
RS
2
Ukraine
2
EA
2
Norway
2
ME
2
New Zealand
2
Croatia
2
San Marino
2
Netherlands
2
Luxembourg
1
Uruguay
1
Panama
1
Austria
1
Malaysia
1
India
1
Germany
1
Morocco
1
Nicaragua
1
Honduras
1
Belgium
1
Guatemala
1
Peru
1
Georgia
1
Jordan
1
Cuba
1
Costa Rica
1
Ecuador
1
Colombia
1
Tunisia
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic